An ongoing trial of the GLP-1 receptor agonist semaglutide for type 2 diabetes and CKD is ongoing (clinical trial registration no
Semaglutides half-life is approximately 7 days
"I'm worried about compounded medication quality." It's the most common concern and a reasonable one with a specific answer available if you ask for it
If youve spent any time this past year scrolling on social media or watching the news, youve likely heard about GLP-1 microdosing and its wide array of benefits: fewer side effects, lower cost, and long-term results
GLP-1 medications arent recommended during pregnancy because the research we have suggests they could be linked to issues with fetal growth and development, birth defects, and pregnancy loss
The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy